Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: HPV-16 vaccine Clear all

Conditions: Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions: E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine; Biological · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Bethesda, Maryland • New Brunswick, New Jersey

Conditions: Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Interventions: pNGVL4aCRTE6E7L2; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 19 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama • Baltimore, Maryland

Conditions: Human Papillomavirus Infections
Interventions: Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more

Conditions: Head and Neck Cancer
Interventions: DNA Vaccine, Cyclophosphamide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adult Solid Tumor
Interventions: SQZ-AAC-HPV, Ipilimumab, Nivolumab; Biological · Drug
Lead sponsor: SQZ Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Duarte, California • La Jolla, California • Detroit, Michigan + 3 more

Conditions: Human Papillomavirus
Interventions: Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®; Biological
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Anal Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Penile Cancer, Vulvar Cancer
Interventions: human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 6
States / cities: Bethesda, Maryland • Boston, Massachusetts • Morristown, New Jersey + 1 more

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Quadrivalent HPV vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 45 Years · Female only
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 56
States / cities: Birmingham, Alabama • Alhambra, California • La Jolla, California + 37 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: MAGE-A3, HPV-16 vaccine; Biological
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cervical Cancer
Interventions: human papillomavirus 16 E7 peptide, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Squamous Cell Carcinoma of the Oropharynx
Interventions: ISA101b; Drug
Lead sponsor: ISA Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Duarte, California • San Francisco, California • Aurora, Colorado + 5 more

Conditions: HPV Infection
Interventions: pBI-11 (3 doses), pBI-11 (1 dose), Placebo (2 doses); Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama • Baltimore, Maryland

Conditions: HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma
Interventions: TG4001, Avelumab; Biological · Drug
Lead sponsor: Transgene; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Adult Solid Tumor
Interventions: SQZ-eAPC-HPV, Pembrolizumab; Biological
Lead sponsor: SQZ Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: Scottsdale, Arizona • Duarte, California • Aurora, Colorado + 5 more

Conditions: Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: HB-201, HB-202, Carboplatin, Paclitaxel, Transoral Robotic Surgery; Drug · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: High-risk HPV Infection and Biopsy-proven CIN1
Interventions: R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7; Biological
Lead sponsor: PDS Biotechnology Corp.; Industry
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Port Jefferson, New York • The Bronx, New York

Conditions: Cervical Cancer, Precancerous Condition
Interventions: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL
Interventions: GTL001+, Aldara; Drug
Lead sponsor: Genticel; Industry
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Louisville, Kentucky • Raleigh, North Carolina • Columbus, Ohio + 1 more

Conditions: Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
Interventions: HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 17 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy; Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HPV 16 Infection, HPV-Related Carcinoma, Recurrence, Metastatic Cancer
Interventions: pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Recurrent Human Papillomavirus Type 16 Associated Cancer
Interventions: HPV 16 TA-CIN; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 19 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama • Baltimore, Maryland

Conditions: HPV 16+ Recurrent or Metastatic Cancer
Interventions: CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16, Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infections, Papillomavirus
Interventions: HPV 16/18 L1 AS04, HPV-16/18/31/45 L1 AS04 Formulation 1, HPV-16/18/31/45 L1 AS04 Formulation 2, HPV-16/18/31/45 L1 AS04 Formulation 3, HPV-16/18/31/45 L1 AS04 Formulation 4, HPV-16/18/31/45 L1 AS04 Formulation 5, HPV-16/18/31/45 L1 AS04 Formulation 6; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 383 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Aurora, Colorado • Golden, Colorado • Kingston, Rhode Island + 1 more

Search by objective public record fields.

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients

Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

A Phase I Clinical Trial of an HPV Therapeutic Vaccine

Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck

Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection

TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.